Cite
HARVARD Citation
Morris, M. et al. (2019). Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European journal of cancer. pp. 107-116. [Online].